Prenetics Global Limited
Prenetics Global Limited (PRENW) Stock Overview
Explore Prenetics Global Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
88.7M
P/E Ratio
-2.15
EPS (TTM)
$-11.04
ROE
-0.28%
PRENW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Prenetics Global Limited (PRENW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 55.16, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.01.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.15 and a market capitalization of 88.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Sheng Wu Yeung
285
Unit 701-706, K11 Atelier King’s Road, Quarry Bay
1970